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Abstract
Chronic lymphocytic leukaemia (CLL) is a heterogeneous disease with a very variable
clinical  outcome.  New  biological  markers,  such  as  cytogenetic  abnormalities  or
mutation status, have become important prognostic factors. Whole-genome sequenc‐
ing studies have revealed novel genomic mutations, NOTCH1, SF3B1, BIRC3, TP53 and
MYD88 being the most important. All these mutations have also been associated with
the disease outcome. The treatment of CLL has evolved favourably in recent years.
However, adverse events or chemorefractoriness occurs in some cases. Luckily, an
increasing number of compounds are under development with promising results. Some
of these new targeted therapies include B-cell receptor inhibitors, new anti-CD20
antibodies, Bcl-2 inhibitors, immunomodulatory drugs or chimeric antigen receptors
(CARs). In this chapter, we will conduct a review of the new prognostic markers of
CLL, the relationship they have with each other to build prognostic scores, the role they
have in guiding treatment decisions and the novel therapies that have emerged recently
with immunologic, biochemical and genetic targets.
Keywords: Chronic lymphocytic leukaemia, genetic abnormalities, recurrent muta‐
tions, targeted therapy, signalling pathway
1. Introduction
Chronic lymphocytic leukaemia (CLL) is a neoplasm characterized by the proliferation and
accumulation of monoclonal mature B lymphocytes in the peripheral blood, bone marrow,
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spleen and lymph nodes. It is the most frequent type of leukaemia in adults from Western
countries, showing a predilection for the elderly, with a median age at diagnosis of 72 years
old. It has been more prevalent in men than in women [1, 2].
The clinical course of CLL is highly heterogeneous. Some patients require treatment at the
time  of  diagnosis,  while  others  remain  asymptomatic  and  may  even  never  be  treated.
Therefore, median survival times range from a few months to many decades [3,4]. In order
to define disease extent and prognosis, Rai and Binet staging systems were designed around
35–40 years ago and remain widely used in clinical practice [5,6]. They are based on physical
examination and blood counts and are therefore inexpensive and easy to apply. Howev‐
er, some patients with early stages promptly progress and do not respond to therapy. For
these reasons, over the last ten years, several biological markers such as immunoglobulin
heavy-chain variable region (IGHV) mutation status, cytogenetic abnormalities or expres‐
sion of specific proteins on CLL cells  have become important prognostic factors for this
disease [7–10].  They are available  in routine clinical  practice and may even guide treat‐
ment decisions.  Recently,  the improvements in the next-generation sequencing technolo‐
gies have revealed novel genomic markers with important prognostic value highlighting
NOTCH1 (neurogenic locus notch homolog protein 1), SF3B1 (splicing factor 3B subunit 1),
BIRC3 (baculoviral IAP repeat-containing protein 3), TP53 (tumour protein p53) and MYD88
(myeloid  differentiation  primary  response  88).  In  the  first  part  of  this  chapter,  we  will
conduct a review of these markers, its implications on pathophysiology and prognosis of
CLL,  the relationship they have with other  prognostic  factors  in  order  to  establish new
scores for clinical practice, and the role they have in guiding therapeutic choices.
CLL remains an incurable disease with the exception of allogeneic transplantation. Besides,
some patients without treatment present survival rates similar to the normal population,
and no benefit  has been found when early treatment has been applied in this subset of
patients. In addition, spontaneous cure has been reported in rare occasions [11]. For these
reasons, only half of the patients diagnosed with CLL will require treatment during follow-
up. Fortunately, survival rates of patients with CLL have improved significantly, thanks to
the great  advances in treatment over the past  decades [12].  Glucocorticoids and alkylat‐
ing drugs were the first treatments introduced, followed by purine analogues. Later, the
arrival of targeted antibody therapy led by rituximab (anti-CD20) was the most revolution‐
ary progress. Bendamustine, another alkylating agent used in Germany for more than 30
years, has also been approved for the treatment of CLL after showing its benefits for this
disease  in  clinical  trials  [13,14].  All  these  drugs  remain  widely  used  in  routine  clinical
practice,  mainly  in  combination  regimens.  In  fact,  chemo-immunotherapy  regimens  are
nowadays  the  standard  approach  to  therapy  of  most  patients  with  CLL,  as  they  have
demonstrated to produce a survival benefit with durable remissions [15–17]. Table 1 sums
up approved drugs for the treatment of CLL by categories; and Table 2 summarizes the
combination of suggested treatment regimens used for the treatment of CLL recommend‐
ed by the NCCN (National Comprehensive Cancer Network) [17].
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Alkylating agents
Chlorambucil
Cyclophosphamide
Bendamustine
Purine analogues
Fludarabine
Pentostatin
Cladribine
Monoclonal antibodies
Anti-CD20
Rituximab
Ofatumumab
Obinutuzumab
Anti-CD52
Alemtuzumab
B-cell receptor inhibitors
Ibrutinib
Idelalisib
Table 1. Approved drugs by categories for the treatment of CLL
Acronym Drugs
FCR Fludarabine, cyclophosphamide, rituximab
FR Fludarabine, rituximab
PCR Pentostatin, cyclophosphamide, rituximab
BR Bendamustine, rituximab
Chlorambucil + anti-CD20 Rituximab/obinutuzumab/ofatumumab
HDMP + rituximab High-dose methylprednisolone, rituximab
RR Lenalidomide, rituximab
RCHOP Rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone
Idelalisib + rituximab Idelalisib, rituximab
Alemtuzumab + rituximab Alemtuzumab, rituximab
Table 2. Combination suggested treatment regimens used for the treatment of CLL recommended by the National
Comprehensive Cancer Network (NCCN) Version 1-2015
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Nevertheless, some of these regimens are not exempted from adverse events that limit their
use in frail patients, especially the elderly. Moreover, some patients are chemo-resistant to
these drugs, and a curative therapy is still absent for them. Knowledge of the pathogenesis of
B-cell receptor (BCR) has led to the investigation of novel molecular targets like Bruton tyrosine
kinase inhibitors or phosphatidylinositol 3-kinases (PI3Ks). New anti-CD20 antibodies such
as ofatumumab or obinutuzumab have also been shown to have a promising activity in CLL.
Other new target therapies under study include Bcl-2 inhibitors, immunomodulatory drugs
(lenalidomide) or chimeric antigen receptors. The second part of this chapter will be dedicated
to review novel therapies that have emerged recently with immunologic, biochemical and
genetic targets.
2. Prognostic markers and risk stratification of CLL
The clinical course of CLL is extremely variable. Prognostic markers are important not only
for patient management but also in understanding the disease biology. Many biological factors
have been added to the classic staging systems of Rai and Binet with the intention to establish
prognostic groups. However, as novel cytogenetic and molecular findings are discovered, our
understanding on its prognostic value keeps in constant evolution. In this section, we will
conduct a review of these “new” prognostic markers, focusing on genetic markers.
2.1. Genetic markers in CLL
2.1.1. Recurrent genomic abnormalities detected by interface fluorescence in situ hybridization (FISH)
FISH studies are able to detect clonal genomic aberrations in the majority (>80 %) of CLL
patients. The most common recurrent chromosomal abnormalities include 13q deletion (13q-),
11q deletion (11q-), trisomy 12 (+12) and 17p deletion (17p-), defining five prognostic categories
with different survival times [18].
2.1.1.1. 13q-
13q- is the most frequent chromosome aberration in CLL, observed in approximately 55 % of
the cases, and entails the group of patients with a better prognosis. However, the deletions
that occur at this chromosome are not homogeneous and neither is the prognosis for this
subgroup of patients. The size of the deletion varies thumping. Two types of deletion have
been proposed in accordance to their extent: 13q- type I or short deletions not comprising the
RB1 (retinoblastoma 1) locus and 13q- type II or large deletions including the RB1 locus. The
latter have been associated with a more aggressive clinical course [19,20]. 13q deletions are
monoallelic in most cases, but biallelic losses have also been described in nearly 30 % of
patients, and although it has been controversial, they do not seem to entail a worse clinical
outcome [21–24]. The size of the clone harbouring 13q- has also implications on prognosis,
with a significantly shorter time to first treatment (TTFT) and overall survival (OS), if a high
proportion of cells carry 13q- [22,25,26]. With intent to explain the pathogenesis and clinical
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heterogeneity of 13q-, several genes located at 13q have been identified. Among them stand
microRNAs (miRNAs) miR15a and miR16-1, DLEU2, DLEU7 or RB1. MiR15a and miR16-1
exhibit a tumour suppressor function in CLL by targeting the BCL-2 oncogene, being absent
or downregulated in the majority of the cases [27,28].
2.1.1.2. 11q-
Prevalence of 11q deletions is estimated below 20 % [18]. The presence of 11q- entails bad
prognosis, and often patients present with progressive disease, B symptoms, bulky lympha‐
denopathy, short TTFT and a reduced OS. In addition, 11q- is associated with unmutated IGHV
status (U-CLL), which is consistent with the poor prognostic factors mentioned [29,30].
However, some evidence points out that the addition of immunotherapy to classic chemo‐
therapy may overcome the effect of 11q- in previously untreated patients [15,31]. Analogously
to 13q-, a high percentage of cells with 11q- has been associated with a worse outcome among
11q- patients [32,33]. 11q- usually implies the loss of the ATM (ataxia telangiectasia mutated)
gene, albeit ATM mutations have been found in <30 % of 11q- cases. ATM gene is involved in
the repair of damaged DNA; hence, its deficiency causes genomic instability and allows the
accumulation of additional genetic mutations during disease course [34]. BIRC3 gene is also
located on 11q close to the ATM gene, and deletions and mutations of this gene lead to an
unfortunate outcome as well, as they tend to appear in fludarabine-refractory patients [35].
2.1.1.3. +12
Trisomy 12 is the third most frequent cytogenetic aberration, occurring in up to 15 % of CLL
cases. Patients with this aberration have been classically considered to have an intermediate
prognosis; however, further work has considered this trisomy as a clinical heterogeneous
entity [36]. +12 has been associated with an atypical morphology and immunophenotype [37]
and has been connected with concurrent trisomy of chromosomes 18 and 19 [38]. Critical genes
involved in this aberration remain unknown. NOTCH-1 mutations were identified in 30–40 %
of patients carrying +12, conferring a worse clinical outcome when present in this subset of
patients [39–41]. Similarly to deletions, among patients with +12, a high percentage of cells
carrying +12 is associated with a worse OS and TTFT [42].
2.1.1.4. 17p-
17p deletion is observed in around 7 % of untreated CLL cases, but its incidence may amount
up to 45 % in cases of relapsed or refractory CLL [43]. 17p- is invariably associated with a very
poor outcome because of the loss of TP53 gene. In more than 75 % of the cases with 17p-,
mutations in TP53 are observed in the remaining allele [44]. In spite of that, monoallelic
inactivation of TP53 may be enough to confer a poor prognosis [45]. The tumour suppression
p53 acts by inducing apoptosis or cell cycle arrest when DNA is damaged, and consequently
genomic complexity is not a rare find in this setting [46]. As in other cytogenetic abnormalities,
a high percentage of deleted cells has been associated with a worse outcome within 17p-
patients [47]. Patients with 17p- usually do not respond to conventional therapies (fludarabine
or alkylating agents), as they are based on p53-dependent mechanisms. Thus, these patients
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relapse more frequently and have a shorter OS [48]. Nowadays, 17p- is the only cytogenetic
abnormality that defines a different treatment approach. Rational options for these patients
include new B-cell receptor inhibitors or methylprednisolone +/- alemtuzumab or rituximab
followed by allogeneic bone marrow transplantation in candidates for this procedure.
2.1.2. IGHV mutation status
The somatic hypermutation of the variable region of the immunoglobulin heavy-chain genes
(IGHV) has become one of the most stable and reliable indicators of clinical outcome in CLL.
Based on the cutoff value of 98 % identity with the closest germ line IGHV, two different subsets
of CLL can be indentified: mutated CLL (M-CLL) and unmutated CLL (U-CLL) [8,9]. Somatic
mutations of IGHV occur in approximately half of the cases and usually present with non‐
progressive disease, in contrast to patients with U-CLL who have a more aggressive disease
with a shorter progression-free survival (PFS), TTFT and OS. U-CLL is also associated with
unfavourable prognostic factors such as 11q-, 17p- or ZAP-70 positivity. Furthermore,
irrespective of mutation status, some heavy-chain variable regions have been associated with
specific clinical features, outcome and varying occurrences from country to country. For
example, IGHV1-69 gene has been observed to be one of the most frequently rearranged genes
in Western patients and is almost always associated with the subset of U-CLL [49]. Other
subgroups reported to be frequently used in Western patients are IGHV3-23, IGHV4-34 and
IGHV3-07. Moreover, an overrepresentation of the IGHV3-21 gene has been reported in
northern European countries compared to the Mediterranean region, and it has been associated
with a worse prognosis despite the mutation status [50].
2.1.3. Mutations of key tumour suppressor genes
2.1.3.1. TP53 mutations
CLL harbours TP53 mutations in around 5–10 % of the cases at diagnosis, but the incidence
increases up to 40–50 % in refractory patients or Richter transformation. TP53 mutations
separate a group of patients with critical importance in CLL. This mutation is associated with
an ominous outcome due to chemo-refractoriness and therefore is the only biomarker that
currently drives treatment decisions in CLL. TP53 mutations have a detrimental impact on
therapy response, PFS and OS [45,48]. TP53 is a tumour suppressor gene that induces apoptosis
or cell cycle arrest after DNA damage. Chemo-refractoriness in patients with these mutations
is explained by the mechanism of action of fludarabine or alkylant agents, based on a p53-
dependent mechanism. Thus, analogously to 17p-, these patients should be treated, avoiding
DNA-damaging chemotherapy agents. Very limited efficient options have been available in
the last years in spite of allogeneic stem cell transplantation. Luckily, a number of novel
biological drugs such as B-cell receptor inhibitors have been developed and incorporated in
the treatment of these patients with encouraging results [51]. Although TP53 mutations are
usually accompanied by 17p-, some patients carry TP53 mutations in the absence of 17p-.
However, the monoallelic TP53 alteration has the same negative impact in prognosis than
biallelic defects [44]. TP53 mutations may appear in a nondominant clone of CLL cells. Ultra-
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deep next-generation techniques were used with the purpose of identifying these subclones,
and TP53 mutations were observed in around 9 % of the cases. These patients showed the same
poor survival than patients with TP53 mutations in the predominant clone [52].
2.1.3.2. ATM gene mutations
ATM gene encodes for the ATM protein kinase, a member of the PI3K (phosphatidylinositol
3-kinase) family. ATM protein takes part in the DNA damage repair mechanism, mediating
cellular response to DNA damage in the form of double-strand breaks [53]. The ATM gene is
located on chromosome 11, and mutations in this gene occur in around 12 % of CLL cases [54].
As mentioned before, 11q- is not frequently associated with ATM mutations (30 % of cases),
although 11q- almost always implies the loss of ATM. Similarly to TP53 and 17p-, mutations
in the ATM gene entail bad prognosis despite its association with 11q-. Therefore, ATM
mutations entail short OS, with a more aggressive disease and poor response to chemotherapy,
and are related to U-CLL [54]. Another relevant finding concerning ATM gene is that biallelic
inactivation carries a worse clinical outcome, with more treatment resistance compared to
monoallelic alterations [55].
2.1.4. Novel gene mutations
New deep sequencing technologies have discovered in the last five years novel recurrent
mutations in CLL, NOTCH1, SF3B1, BIRC3 and MYD88 being the most frequent [56–58]. These
mutations can be observed in approximately 10–15 % of CLLs. Table 3 summarizes the most
common mutations with their principal features.
Gene
mutations Chromosome Association Biologic function
Clinical
outcome Frequency
NOTCH1 9 +12 NOTCH1 signalling Poor 10–15 %
SF3B1 2 11q- mRNA splicing Poor 5–10 %
BIRC3 11 11q- NF-κB pathway Poor 4 %
MYD88 3 13q- NF-κB pathway Good 3 %
ATM 11 11q- DNA repair Poor 12 %
TP53 17 17p- DNA repair Dreadful 5–10 %
Table 3. Most frequent recurrent mutations in CLL
2.1.4.1. NOTCH 1
NOTCH1 mutations occur in around 10–15 % of de novo CLL cases, being more frequent in
advanced disease or Richter transformation [59]. These mutations result in the generation of
a truncated protein which lacks the C-domain, becoming more stable in activating the
NOTCH-1 signalling pathway. This protein in its normal conformation regulates the tran‐
scription of MYC, TP53 genes and molecules of the NF-κB pathway. Therefore, NOTCH1
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mutations allow, an up-regulation of the cell cycle, and consequently, an advantage in cell
survival and apoptosis resistance [41,58]. NOTCH1 mutations confer to CLL a worse clinical
outcome with a shorter TTF, PFS, OS and less response to treatment even in the context of a
rituximab-based regimen. In connection with this, bad prognostic markers have been associ‐
ated with NOTCH1 mutations. Among them, ZAP-70, CD38 and U-CLL stand out [60]. It is
worth noting that approximately 30 % of cases with Richter transformation harbour NOTCH1
mutations. However, it is unclear whether this mutation is acquired during progression
disease, as a consequence of clonal evolution or can be observed in early stages of CLL [41,59].
NOTCH1 mutations have also been associated with +12, and when both alterations cluster,
NOTCH1 separates a subgroup of patients with poor outcome [40]. NOTCH1 mutations have
also been identified in 60 % of cases with T-acute lymphoblastic leukaemia and other non-
haematological neoplasms, and its role among them can be ambiguous, acting not only as an
oncogene but also as a tumour suppression gene. The relevance of these mutations is even
greater as they can be used as a target for therapy. In fact, drugs for this purpose are under
development [61].
2.1.4.2. SF3B1
SF3B1 gene is located at chromosome 2q33.1 and encodes for a splicing factor. Different
mutations related to the splicing machinery have been associated with oncogenesis, pointing
out that aberrant splicing constitutes an important pathway in malignant transformation.
Nevertheless, the real mechanism underlying SF3B1 dysfunction in CLL remains unknown. It
is speculated that SF3B1 mutations may trigger aberrant splicing of important proteins for the
tumourigenesis process including cellular cycle control, angiogenesis or apoptosis. Somatic
mutations of SF3B1 can be found in around 10 % of CLL cases, but the incidence increases
during disease evolution, probably determining the appearance of aggressive subclones [56].
SF3B1 mutations in CLL entail bad prognosis with a more aggressive disease, advanced clinical
stage at diagnosis and a worse OS, being more frequently observed in fludarabine refractory
patients [62]. Bad prognosis markers such as ZAP-70 and U-CLL have also been associated
with these mutations. In contrast, Richter transformation is not an often issue among SF3B1
mutations [59]. In around 50 % of the cases, SF3B1 mutations occur accompanied by 11q- or
ATM mutations, and although unusual, mutations in SF3B1 and ATM have been observed
without 11q-. Other haematological diseases such as myelodysplastic syndromes and non-
haematologic tumours may harbour SF3B1 mutations, but they seem mutually exclusive from
other lymphoid neoplasms. In contrast to CLL, SF3B1 mutations confer a more favourable
prognosis in myelodysplasia and identify a particular entity: refractory anaemia with ring
sideroblasts [63,64].
2.1.4.3. BIRC3
BIRC3 mutations are unusual in CLL, with an incidence of 4 % approximately. The BIRC3 gene,
located near ATM gene at 11q33, together with TRAF2 and TRAF3 conforms a protein that
negatively regulates the activation of the NF-κB signalling pathway. BIRC3 mutations result
in an activation of the NF-κB pathway, hence resistance to apoptosis and increased prolifera‐
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tion of cells. BIRC3 mutations were found in cases of relapse or fludarabine resistance,
especially in the absence of TP53 mutations. In this setting, the incidence of these mutations
rises up to 25 %. Anyway, when they appear at diagnosis, a poor clinical outcome is also
observed [35]. NF-κB inhibitors are under development in CLL cases harbouring BIRC3
mutations with encouraging preclinical results [65].
2.1.4.4. MYD88
MYD88 protein takes part in the homeostasis of B human cells working as an adaptor protein
of the toll-like/interleukine-1 receptor. MYD88 mutations cause resistance to apoptosis after
they activate the NF-κB pathway. MYD88 mutations have been found in several lymphoid
neoplasms, distinguishing lymphoplasmacytic lymphoma [66,67]. In CLL, they have been
reported in a low proportion of cases (3–5 %) [57,58]. In contrast to previous recurrent
mutations, mutations in MYD88 have been associated with a good outcome in CLL patients.
They have also been observed more frequently in young patients and detected in association
with 13q- and M-CLL, maintaining the favourable prognosis in these populations [68].
2.1.5. Other genetic abnormalities with prognostic relevance
Other genetic abnormalities have been reported in CLL in a very low proportion of cases. These
include deletion of 6q, trisomy 3, trisomy 8, trisomy 18, trisomy 19, deletion of 5q and gains of
2p, 3q, 17q and 8q. These alterations have also been related to disease outcome in a recent study
that used array comparative genomic hybridization to identify genomic imbalance. Three
groups of patients were made according to their prognostic outcome: good outcome (13q-
without any of these alterations: gain, 1p, 7p, 12, 18p, 18q, 19, and loss, 4p, 5p, 6q, 7p), adverse
outcome (gain, 2p, 3q, 8q, 17q, and loss, 7q, 8p, 11q, 17p, 18p) or intermediate outcome
(remainder). This study also identified gain of 3q, 8q and 17p- as independent unfavourable
prognostic biomarkers [69]. Translocations are also rare in CLL, but when present, they entail
a negative prognostic impact [70]. Finally, complex karyotypes, defined by 3 or more altera‐
tions, whether deletions or gains, have also been associated with progressive or refractory
disease and ATM and TP53 defects [10,38].
2.2. Other prognostic biomarkers in CLL
Many non-genetic markers predict disease outcome in CLL. A brief enumeration of them and
their implication in prognosis will be detailed below. Serum markers LDH and β2-microglo‐
bulin have been widely used, indicating a more advance disease when their levels are high,
and although they are not specific for CLL, they can be easily measured in clinical practice [71].
Lymphocyte double time, defined as the number of months that takes the lymphocyte count
to double, is another classic prognostic marker that can be easily used in CLL. Hence, it has
been proposed as one of the criteria to indicate therapy [72]. Several protein markers were
investigated with the intention to find substitute markers for the arduous IGHV mutation
status. Among them, CD38, ZAP70 (zeta-chain-associated protein) and CD49d stand out. CD38
and ZAP70 were first described as surrogate markers for U-CLL, but this has been controversial
[7,9]. However, further studies demonstrated that both are independently associated with poor
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outcome regardless of mutation status [9,73,74]. CD49d has also been correlated with shorter
survival times when expressed at high levels and has recently emerged as the strongest flow
cytometry predictor for OS [75]. MicroRNAs are small non-coding RNA molecules which act
as posttranscriptional regulators of gene expression. Its dysregulation is associated with
tumour development, and in CLL, they might be used as prognostic markers, as some studies
have demonstrated. For instance, reduced expression of miR-29, mir-223, miR-34a and mir-181
or increased expression of miR-21 and mir-221/222 has been associated with poor prognosis
[38]. However, to validate this data, corroboration in prospective studies is necessary.
2.3. Prognostic systems
Numerous prognostic markers have individually shown correlations with survival over the
last decades. The current challenge is to build a prognostic model that is clinically relevant,
easily applicable, oriented to take therapeutic decisions and feasible in the clinical practice
setting. With these goals, some attempts have been done over time. A review of some of these
models is summarized in Table 4 and detailed next [76].
Authors Markers used Prognostic groups
Rai et al. -Haematological blood counts
-Physical examination
Low: lymphocytosis
Intermediate: lymphadenopathy, visceromegaly
High: anaemia or thrombocytopenia
Binet et al. -Haematological blood counts
-Physical examination
A: < 3 areas lymphadenopathy
B: no A, no B
C: anaemia or thrombocytopenia
Döhner et al. -FISH 13q-: median overall survival (OS) of 133 months
Normal karyotype: 111 months
+12: 114 months
11q-: 72 months
17p-: 32 months
Wierda et al. -Age
-Absolute lymphocyte count
-β2-microglobulin levels
-Rai stage
-Sex
-Number of lymph node regions
Calculate the 5-year and 10-year survival probability with
specific nomogram
Wierda et al. -LDH
-Number of lymph node regions
-Size of lymph nodes on the neck
-IGHV mutation status
-FISH aberrations
Calculate the 2-year and 4-year treatment-free probability with
specific nomogram
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Authors Markers used Prognostic groups
Pflug et al. -Sex
-Age
-ECOG status
-17p- (six points)
-11q-
-IGHV mutation status
-β2-microglobulin levels
-Thymidine kinase
Male, 1 point; TK >10 U/L, 2 points; β2-microglobulin 1.7–3.5
mg/dL, 1 point; β2-microglobulin >3.5 mg/dL, 2 points;
unmutated-CLL (U-CLL), 1 point; ECOG >0, 1 point; 11q-, 1
point; age >60 years, 1 point
Low risk: score 0 to 2
Intermediate risk: score 3 to 5
High risk: score 6 to 10
Very high: score 11 to 14
Rossi et al. -FISH
-New mutations
Very low risk: 13q- only
Low risk: +12 or a normal FISH
Intermediate risk: NOTCH1 and/or SF3B1 and/or 11q-
High risk: TP53 and/or BIRC3 abnormalities
Haferlach et al. -Age
-Leucocyte count
-IGHV mutation status
-IgH translocations
-Number of cytogenetic aberrations
-TP53 deletion
-ATM mutations
Predicting OS:
Age ≥ 65 years, 1 point; leucocyte count ≥20 × 109/l, 1 point; U-
CLL,1 point; TP53 deletion, 2 points; translocation involving
the IGH locus on 14q32, 2 points; number of chromosome
aberrations based on CBA 0, 0 points; 1 or 2, 1 point; and ≥3, 2
points
Favourable risk: 0–3 points
Intermediate risk: 4–5 points
Unfavourable risk: "/>5 points
Predicting TTFT:
U-CLL, 1 point; ATM deletion, 1 point; translocation involving
the IGH locus on 14q32, 2 points; number of chromosome
aberrations based on CBA 0 or 1, 0 points; 2–4, 1 point; and ≥5,
2 points
Favourable risk: 0–2 points
Intermediate-1 risk: 3 points
Intermediate-2 risk: 4 points
Unfavourable risk: 5 points
Table 4. Summary of published prognostic indexes for CLL
Rai and Binet prognostic systems [5,6] were the initial scores intended to predict progno‐
sis in patients with CLL. These score systems still stand in routine clinical practice nowadays
as they are good predictors for prognosis,  inexpensive and able to identify the need for
therapy. The biggest disadvantage of them is that a notable amount of patients with early
stages  progress.  Wierda  et  al.  [71]  developed  a  nomogram  including  age  and  absolute
lymphocyte count, β2-microglobulin levels, Rai stage, sex and number of involved lymph
node regions.  A specific  punctuation was given to  each independent  covariate,  and the
summation of the points hurls a new score that can be extrapolated to calculate the 5- and
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10-year probability of survival. This model may be useful for previously untreated patients,
but  its  limitations  include  that  it  was  performed  in  a  young  cohort  of  patients,  not
extrapolated  to  all  CLL  patients,  and  that  new  biological  markers  were  not  included.
However,  this  nomogram  has  been  validated  later  in  an  independent  multicentre  CLL
population  and  improved  by  simplifying  it  into  a  four-variable  model  (age,  sex,  Binet
staging,  β-2-microglobulin)  [77].  The  development  of  FISH  studies  identified  genomic
aberrations in around 80 % of CLL patients and led to the stratification into a hierarchy of
five prognostic  subgroups with decreasing survival  times:  CLL cases  with 17p-  had the
worst prognosis (median survival of 32 months), followed by cases harbouring 11q- (median
survival of 72 months), +12 (median survival of 114 months), normal karyotype (median
survival of 111 months) and 13q- (median survival of 133 months) [18]. This model supposed
a great achievement to powerfully complement the Rai and Binet prognostic scores and
allows  to  make  therapeutic  decisions  such  as  to  offer  a  different  treatment  to  17p-  pa‐
tients. The next step was to include classical and new biological and genetic markers in the
same prognostic score. In line with this, Wierda et al. [78] proposed a new nomogram, this
time including new prognostic markers,  with the purpose to calculate the 2-  and 4-year
probability of TTFT. Along with LDH, the number of involved lymph node sites and large
size of lymph nodes of the neck, new biological factors such as IGHV mutation status and
FISH aberrations according to the hierarchal model were included. This model has not been
validated in independent cohorts and has not been used to calculate OS. Nevertheless, it
can be useful to identify patients at high risk for progression to treatment.  The German
CLL Study Group came up with another prognostic system based on 23 classical and novel
biological and genetic markers [79]. Eight factors were finally independently associated with
inferior  survival:  sex,  age,  ECOG  status,  17p-,  11q-,  IGHV  mutation  status,  serum  β2-
microglobulin  levels  and  serum thymidine  kinase.  According  to  these  factors,  four  risk
categories  could  be  separated  with  different  survival  times.  This  prognostic  score  was
validated in an independent cohort. Comparing with classic staging systems, this prognos‐
tic score allows to identify early-stage patients who will sooner progress and to separate
ultrahigh-risk patients. However, there are some barriers to adopt this score into clinical
practice  including  that  thymidine  kinase  is  not  available  routinely;  new data  regarding
novel  mutations such as NOTCH1, SF3B1  or  BIRC3  has not  been incorporated;  and p53
mutations in patients without 17p- were not represented. Haferlach et al. proposed two new
scoring  systems  with  a  combination  of  genetic  and  classical  markers.  The  parameters
incorporated were age, leukocyte count, IGHV mutation status, IgH translocations, number
of chromosomal aberrations detected with CBA (chromosome banding analysis) and TP53
and ATM  mutations. The applicability of these scores in the current setting is limited, as
CBA is not commonly performed in clinical practice. Rossi et al. [80] were the first to propose
a scoring system integrating both cytogenetic and mutational markers. This scoring system
separates CLL patients into four prognostic risk groups: high risk, harbouring TP53 and/or
BIRC3  abnormalities  (10-year  OS:  29  %);  intermediate  risk,  harbouring  NOTCH1  and/or
SF3B1  mutations  and/or  11q-  (10-year  OS:  37  %);  low risk,  harbouring +12 or  a  normal
genetics (10-year OS: 57 %); and very low risk, harbouring 13q- only, whose 10-year OS
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(69.3 %) did not significantly differ from a matched general population. This model exhibits
superiority in discrimination patient outcome to the FISH-based model and can be used at
any  time  point  from  diagnosis,  maintaining  its  prognostic  relevance.  It  emphasizes  the
importance of including new recurrent mutations, as these may reclassify patients into a
higher-risk group. Other authors partially replicated this scoring system although finding
some discrepancies that suggested that NOTCH1 and SF3B1  mutations should be consid‐
ered as higher-risk alterations [81,82].
3. Targeted therapy for CLL
Immuno-chemotherapy is the initial approach to the majority of CLL patients who require
therapy nowadays. However, some patients relapse, become refractory or suffer important
secondary adverse events. For these reasons, the emergence of new targeted treatments has
and will revolutionize the treatment model for CLL. Hopefully, targeted therapy will be not
only more effective in improving survival of CLL patients but also less toxic, ameliorating
quality of life of patients under treatment. This part of the chapter will be dedicated to review
the novel targeted treatments that have been already approved or are being studied for the
treatment of CLL.
3.1. Second-generation anti-CD20 monoclonal antibodies
CLL cells express antigen CD20 with a low intensity, but enough for the chimeric mouse
anti-human CD20 monoclonal  antibody rituximab to  lyse  these  cells.  Rituximab acts  by
different  mechanisms  including  antibody-dependent  cell-mediated  cytotoxicity  (ADCC),
complement-mediated  cytotoxicity  and  direct  toxicity.  When  used  in  combination  with
chemotherapy, rituximab has demonstrated superiority over chemotherapy regimens and
has therefore become a standard of care in the treatment of CLL patients either in front‐
line or salvage therapy [14,15].
3.1.1. Ofatumumab
Ofatumumab is a fully humanized anti-CD20 that binds to a different CD20 epitope than
rituximab, generating a greater cytotoxic potential than rituximab by complement-mediated
cytotoxicity with the same ADCC. It has been approved by the Food and Drug Administration
(FDA) and the European Medicines Agency (EMA) for the treatment of fludarabine and
alemtuzumab refractory CLL patients and recently by the FDA for previously untreated
patients in combination with chlorambucil (Clb) in whom fludarabine-based therapy is
considered inappropriate. The study that gave the indication of ofatumumab for previously
treated patients consisted of a phase II trial including 138 patients with either fludarabine and
alemtuzumab refractoriness or fludarabine refractoriness and bulky disease. Overall response
(OR) rates were 58 % and 47 %, and median OS were 13.7 and 15.4 months, respectively. The
most common adverse events were infusion reactions and infections, which were primarily
grade 1 or 2 events [83]. The FDA approval of ofatumumab in combination with chlorambucil
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for previously untreated CLL patients was based on the results of a phase III trial only
preliminary reported, comparing ofatumumab in combination with chlorambucil to single-
agent chlorambucil in 447 patients in whom fludarabine-based therapy was considered to be
inappropriate. The ofatumumab + chlorambucil arm demonstrated superiority with a higher
OR (82 % vs. 69 %), CR (12 % vs. 1 %) and PFS (22.4 vs. 13.1 months) [84]. Anyway, a formal
comparative trial of ofatumumab versus rituximab is missing, and therefore, the real value of
ofatumumab remains to be determined.
3.1.2. Obinutuzumab (GA101)
Obinutuzumab is a new second-generation recombinant humanized anti-CD20, glycoengi‐
neered to increase its affinity in binding the type 2 CD20 epitope. Obinutuzumab produ‐
ces an increased ADCC and direct cytotoxicity, with lower complement-mediated toxicity.
The FDA approved this drug for its use in combination with chlorambucil for the treat‐
ment  of  patients  with  previously  untreated  CLL,  in  view of  the  primary  results  of  the
CLL-11 trial [85]. This study consisted of a phase III international clinical trial that compared
chlorambucil  (Clb)  versus chlorambucil  plus rituximab (R-Clb)  versus chlorambucil  plus
obinutuzumab  (O-Clb)  in  previously  untreated  CLL  patients  not  candidates  to  receive
fludarabine.  Patients  in the O-Clb arm achieved a higher OR rate and a prolonged PFS
compared to  patients  in  the R-Clb arm and a  benefit  in  OS,  PFS and OR rate  than pa‐
tients receiving Clb alone. Grade 3 and 4 neutropenia and infusion reactions were more
common  with  O-Clb  than  with  R-Clb,  but  the  risk  of  infection  was  not  increased.  An
updated analysis of this trial has been recently published, confirming the PFS benefit in the
arm of O-Clb vs. R-Clb (29.2 versus 15.4 months, P<0.001) and reporting a longer TTFT in
the arm of O-Clb vs. R-Clb (42.7 versus 32.7 months, P<0.001). The previously observed OS
benefit of G-Clb over Clb monotherapy was confirmed [86].
3.2. B-Cell receptor signalling pathway
The B-cell receptor (BCR) signalling pathway is vital for CLL cell survival and proliferation
and therefore constitutes an important new strategy for targeted therapy in CLL. Bruton
tyrosine kinase (BTK) or phosphoinositide 3'-kinase (PI3K) constitutes some of the key kinases
in this pathway. Inhibitors of these kinases have been under investigation in patients with CLL
with promising clinical results and minimal toxicity. In fact, ibrutinib and idelalisib, two oral
compounds given as continuous treatment, have been recently approved for treatment of CLL
patients. They have demonstrated high efficacy even in the higher-risk patient subgroup. One
important aspect of treatment with BCR inhibitors is the development of lymphocytosis, often
transient, mediated by the migration of CLL cells from the bone marrow and lymph nodes to
the peripheral blood, where cell survival is decreased.
3.2.1. Ibrutinib
Ibrutinib is an oral small molecule that acts as an irreversible covalent inhibitor of the BTK
resulting in an inhibition of the BCR signalling pathway. It is the first BCR inhibitor approved
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by the FDA and EMA for the treatment of relapsed or refractory CLL and as a first-line
treatment in cases of 17p- or TP53 mutations in patients unsuitable for chemo-immunotherapy.
Ibrutinib was approved in light of the results of a phase Ib/II multicentre clinical trial that
included 85 refractory or relapsed CLL patients to receive ibrutinib at different doses [87]. The
population represented at this trial had a high-risk disease with 33 % of 17p-, 36 % of 11q- and
a median of four prior therapies. The results were encouraging with an OR rate independent
of adverse risk factors of 71 % and an additional 15–20 % of patients with partial response with
persistent lymphocytosis but reduced lymph nodes. The estimated 26-month PFS was 75 %,
suggesting that ibrutinib responses are quite durable. Ibrutinib was well tolerated with
predominant adverse events being grade 1 or 2 including transient diarrhoea, fatigue and
upper respiratory tract infections. Subsequently, a multicentric randomized phase III com‐
pared ibrutinib with ofatumumab in a group of previously treated patients not candidates for
purine analogues [88]. The trial was stopped early after interim analysis because of a significant
improvement in OS and PFS in the ibrutinib arm. The promising results of these trials
prompted out combination studies that are currently ongoing or have been completed.
Combinations of ibrutinib plus rituximab or ibrutinib plus bendamustine and rituximab have
also been explored in different trials that enrolled high-risk, refractory or relapsed CLL
patients, obtaining OR rates between 93 % and 95%, with an acceptable toxicity profile and
being effective even in the subgroups of patients with 17p- or TP53 mutations [89,90]. In
summary, ibrutinib is a well-tolerated drug that has been demonstrated to produce high
response rates even in high-risk CLLs. The combination of ibrutinib with other drugs is under
investigation and will hopefully change the actual paradigm of CLL treatment due to the
encouraging preliminary results. Unfortunately, resistances and progressions to Richter
syndrome have been described with a dismal prognosis in these cases.
3.2.2. Idelalisib (CAL-101)
Idelalisib is an oral selective inhibitor of PI3K that produces apoptosis in CLL cells. It has been
approved by the FDA and EMA for use in combination with rituximab for patients who have
received at least one prior therapy or as first-line treatment in the presence of 17p deletion or
TP53 mutation in patients unsuitable for chemo-immunotherapy. The efficacy of idelalisib in
combination with rituximab was assessed in a multicentre randomized phase III trial that
compared idelalisib plus rituximab with idelalisib plus placebo in patients with relapsed CLL.
Most of the patients enrolled had adverse prognostic factors including 17p-, TP53 mutations
or M-CLL. Idelalisib obtained a higher OR rate than placebo (81 % vs. 13 %, P> 0.001) and a
superior OS (92 % vs. 80 % at 12 months, P=0.02). PFS at 24 weeks was 93 % in the idelalisib
group compared with 46 % in the placebo group (P<0.001). Serious adverse events occurred
in both groups in a proportion of 40 % (idelalisib) and 35 % (placebo). These included pneu‐
monia, pyrexia and febrile neutropenia. The benefit of idelalisib was maintained among
patients with adverse genetic features. Analogously to ibrutinib, lymphocytosis with node
response was observed in some patients [91]. In view of this exciting results, further trials with
idelalisib in combination with bendamustine, fludarabine or chlorambucil in patients with
relapsed or refractory CLL are being performed, confirming the feasibility and benefits of these
combinations [92].
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3.3. Bcl-2 inhibitors
B-cell lymphoma-2 (Bcl-2) proteins, encoded by the Bcl-2 gene, are expressed at high levels in
CLL cells. These proteins contribute to the regulation of the apoptotic process and therefore
constitute an important therapeutic target for CLL.
3.3.1. ABT-263 (navitoclax)
Navitoclax is an orally bioavailable BCL-2 inhibitor that binds to several antiapoptotic BCL-2
family proteins including BCL-2, BCL-XL, BCL-x and BCL-B. A phase I trial conducted to
evaluate the biologic activity, safety and pharmacokinetics of ABT-263 demonstrated encour‐
aging results for this molecule as a single agent, even in patients with fludarabine-refractory
disease, bulky adenopathy or 17p-. However, its therapeutic use was limited because of severe
thrombocytopenia, observed as an important adverse effect in 28 % of the patients due to the
inhibition of BCL-XL.
3.3.2. GDC-0199/ABT-199 (venetoclax)
GDC-0199/ABT-199 is a small molecule reengineered to decrease the thrombocytopenia side
effect of navitoclax. ABT-199 produces a selective inhibition BCL-2 with a reduced effect
on BCL-XL. It has shown promising results in a phase I trial that enrolled 56 refractory or
relapsed CLL patients, 29 % with 17p- and 32 % with fludarabine resistance [93]. The major
side  effects  included  tumour  lysis  syndrome  and  neutropenia.  Interestingly,  ABT-199
yielded an OR rate of 85 %, with 13 % of complete responses and 72% of partial respons‐
es. These encouraging results were also observed in high-risk patients, with a response rate
of 88 % and 75 % in patients with 17p- and fludarabine refractory, respectively. Clearly,
these data indicate that Bcl-2 inhibitors will  play an important role in the future for the
treatment  of  CLL  patients,  and  therefore,  ABT-199  is  currently  being  investigated  in
combination with immuno-chemotherapy.
3.4. Immunomodulatory drugs
Changes in the microenvironment of tumour cells promote the selective survival of malignant
CLL cells preventing apoptosis. Immunomodulatory drugs act by altering cellular features
and the cytokines of tumour microenvironment. In fact, lenalidomide has been shown to be
effective in CLL.
3.4.1. Lenalidomide
Lenalidomide is an oral second-generation immunomodulatory drug with antiangiogenic,
cytokine activity modulating, and immunomodule properties. It has been demonstrated to be
active in MDS, multiple myeloma and lymphoproliferative disorders. The first phase II trials
that tested lenalidomide in relapsed or refractory CLL obtained an OR rate between 32 % and
47 %. The major adverse effects reported were myelotoxicity, tumour flare and tumour lysis
syndrome, all of them ameliorated with lower doses of lenalidomide [94,95]. Lenalidomide
was also tested as a front-line therapy for CLL patients in another two trials with a different
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dosing, but both with a low initial dose (2.5–5 mg daily) and a further escalation to a target of
25 mg. These trials obtained an OR rate between 56 % and 65 %. A high proportion of tumour
flare reactions were observed in one of them, although they were mild. Grade 3 or 4 neutro‐
penia was also frequent but without serious consequences. A recent update of one of these
studies showed that at a median follow-up of 4 years, time to treatment failure had not been
reached and OS was 86 %. These studies showed that lenalidomide is effective as first-line
therapy for CLL and is well tolerated when administered in a dose escalation plan [96–98].
Lenalidomide has also been tested in combination with other drugs. In a phase II trial, patients
with relapsed or refractory CLL received a combination of rituximab and lenalidomide
obtaining an OR rate of 66 % including 12 % of complete responses. Seventy-three percent of
patients showed neutropenia (grade 3 or 4), and only 1 episode of grade 3 tumour lysis was
reported. Another phase II study of lenalidomide and rituximab was performed, this time as
a first-line therapy. The OR rate was 88 %, including 15 % of complete responses. Again,
neutropenia was the most common adverse event [99,100]. Additional combinations are
currently under study, as well as maintenance therapy after chemo-immunotherapy.
3.5. Chimeric antigen receptors
Chimeric antigen receptors (CARs) are engineered constructs that combine the antigen
recognition domain of an antibody with intracellular signalling domains into a single chimeric
protein. CD19 antigen is exclusively expressed in B-cells and therefore is a very suitable target
for the treatment of CLL with CARs. Indeed, a pivot clinical trial proved the important
antitumor activity of this CAR-modified autologous T-cells targeted to CD19 (CART19 cells)
in three patients with refractory CLL [101]. Two out of the three patients achieved a complete
response lasting longer than two years and the other patient a partial stable response. Toxicities
included hypogammaglobulinemia, decreased number of plasma-cells and B-cell aplasia. The
CART19 cells expanded > 1,000-fold in vivo and expressed functional CARs for at least six
months, and a proportion of them persisted as memory CART19 cells. On average, each infused
CAR-expressing T-cell was calculated to eradicate at least 1,000 CLL cells. In another study,
ten patients with refractory CLL or relapsed B-cell acute lymphoblastic leukaemia (ALL) were
treated with CART19 modified to express a second-generation CAR anti-CD19. Three of the
four evaluable patients with bulky CLL who received prior treatment with cyclophosphamide
experienced either a significant reduction or a mixed response in lymphadenopathy without
development of B-cell aplasia. The short-term persistence of infused T-cells was enhanced by
previous administration of cyclophosphamide and was inversely proportional to the tumour
burden in peripheral blood [102]. In addition, a longer follow-up from ten patients treated with
CART19 was reported. The study included nine adults with relapse or refractory CLL, three
patients with p53 deletion and a child with relapsed and refractory ALL [103]. CLL patients
received chemotherapy regimens 4–6 days before CART19 infusions. Four of the nine evalu‐
able patients achieved a complete response, including three patients with CLL. Two additional
patients from the CLL group had a partial response lasting from three to five months, and
three patients did not respond. In the four patients who achieved complete response, maximal
expanded cells in peripheral blood were detected at an average of 27-fold higher than the
infused dose. No patients with complete response relapsed. Patients who responded devel‐
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oped a cytokine release syndrome manifested by fever, as well as variable degrees of anorexia,
nausea, transient hypotension and hypoxia. In responding CLL patients, cytokine levels were
increased, and five patients with cytokine release required treatment. In summary, CART19
can induce potent and sustained responses in patients with advance, refractory and high-risk
CLL. However, further research is needed to ascertain the efficacy of this therapy and minimize
associated cytokine-mediated toxicities.
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